FDA Safety Flag
The FDA has identified this substance as one that may present significant safety risks when used in compounding, including concerns about immunogenicity, impurity characterization, and/or insufficient safety information.
WADA S2
This substance falls under WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). If you are subject to anti-doping rules, this category of substances is prohibited at all times.
GH Axis
This substance modulates the growth hormone axis. GH-axis stimulation carries risks including glucose intolerance, fluid retention, and theoretical concerns about sustained IGF-1 elevation.
Evidence visual
CJC-1295 evidence and risk matrix
intermediate researcher fit
Evidence
Tier B
Risk
high
Regulatory
not approved
WADA
S2
FDA
flagged
Route
subcutaneous
Higher-confidence evidence profile, but regulatory and sourcing checks still matter.
Overview
CJC-1295 is a long-acting GHRH analogue designed to prolong exposure versus native GHRH. Human trials in healthy adults used subcutaneous microgram/kg dosing and showed sustained GH/IGF-1 elevations over days, with IGF-1 effects persisting up to ~2 weeks after single dosing. FDA has flagged CJC-1295 in its compounding safety risk context. Common adverse events include injection-site reactions, headache, diarrhea, flushing, and transient hypotension at higher doses.
Decision path
Where CJC-1295 fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether CJC-1295 belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
Long-acting GHRH analogue that increases endogenous GH secretion and downstream IGF-1; designed to prolong exposure versus native GHRH.
subcutaneous
Human trials: subcutaneous 30-60 µg/kg; sustained GH/IGF-1 elevations observed.
Sustained GH and IGF-1 elevation; body composition modulation (long-horizon, not well-established for consumer outcomes).
Biomarker effects persist multiple days; IGF-1 elevations up to ~2 weeks after single dose.
GH-axis stimulation risks: glucose intolerance, theoretical neoplasia concerns with elevated IGF-1.
Injection-site reactions, headache, diarrhea, flushing, transient hypotension at higher doses.
Monitor insulin/glucose sensitivity, thyroid axis, and cortisol/prolactin. Trials report no significant cortisol/prolactin/TSH/LH increases at 60 µg/kg single dose.
Cost at a glance
Typical cycle cost
$143.98
Estimated monthly
$47.99
Protocol style
8-12 week phase
Phase-based
Estimate confidence
High confidence
Assumes roughly 12 mg–24 mg per cycle, using 2 tracked affiliated listings.
GH-axis compounds are modeled as longer blocks rather than monthly bursts.
Age, sex, and monitoring
Life-stage fit
Midlife is where GH-restoration framing is most often used, but evidence and long-term safety remain limited.
Best fit age ranges: 35-44, 45-54
55-64
Later-life GH-axis escalation raises a higher monitoring and cancer-risk burden.
65+
Generally a poor fit because growth signaling and monitoring burden climb with age.
Sex-specific note
GH-axis support remains a weak area for sex-specific outcome data, so sex should act as a caution signal rather than a targeting rule.
female
Avoid in pregnancy or active conception planning because growth-axis manipulation lacks reproductive safety data.
Monitoring burden
highGH-axis support is not a low-friction decision. IGF-1 and cancer-risk context matter.
Baseline labs and checks
IGF-1, fasting glucose or HbA1c, CMP, blood pressure baseline
Follow-up cadence
Reassess at startup and then roughly every few months if continuing.
Red flags
- excessive IGF-1 elevation
- edema or joint pain
- unusual growth-related symptoms
Known Interactions
GHRH analog + GHS-R agonist may produce additive GH release; multiple GH-axis peptides flagged for safety/characterization concerns.
Additive GH-axis stimulation plausible; FDA flags both compounds in compounding safety-risk context.
Additive GH-axis stimulation plausible (mechanistic); conservative gating.
Oral ghrelin-receptor agonism plus GHRH analog raises GH-axis complexity and glucose-monitoring burden.
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for CJC-1295.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.